TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27745551

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) plus deferoxamine (DFX)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 24652467

Group type: EXPERIMENTAL
Intervention: Rituximab therapy (500 mg or 1000 mg infusions on study days 1 and 15)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rituximab therapy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rituximab therapy with oral corticosteroids during infusion
Number of subjects: 10
Study: 23566945

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM197 (primary immunisation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM197 (before booster immunisation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM197 (one month after booster immunisation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM197 (correlation with antibody persistence)
Number of subjects: 0
Study: 19966539

Group type: EXPERIMENTAL
Intervention: Active vaccination program (educational program to promote vaccination)
Number of subjects: 3646

Group type: COMPARATOR
Intervention: No action (control group)
Number of subjects: 3646
Study: 18197842

Group type: EXPERIMENTAL
Intervention: Early loaded dental implants (n=16)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Delayed loaded dental implants (n=14)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All dental implants
Number of subjects: 15
Study: 15683898

Group type: EXPERIMENTAL
Intervention: Etching with phosphoric acid for 60s
Number of subjects: 80

Group type: COMPARATOR
Intervention: Etching with phosphoric acid for 40s
Number of subjects: 80

Group type: COMPARATOR
Intervention: Etching with phosphoric acid for 20s plus Xeno III (20s)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Etching with phosphoric acid for 40s plus Xeno III (20s)
Number of subjects: 80
Study: 12501967

Group type: EXPERIMENTAL
Intervention: Writing with cognitive change or exposure instructions (20 minutes on 4 days over 2 weeks)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Writing about innocuous topics (control group)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: All subjects (combined group)
Number of subjects: 121
Study: 10029963

Group type: EXPERIMENTAL
Intervention: Triazolam 0.005 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Triazolam 0.015 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Triazolam 0.030 mg/kg
Number of subjects: 30
Study: 7728861

Group type: EXPERIMENTAL
Intervention: Three methods of femoral artery hemostasis
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Restarting heparin postsheath removal
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Number of procedures done during one hospitalization
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Noncompliance of the patient with bedrest after the procedure
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Number of arterial punctures to initiate the procedure
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Preprocedure treatment with corticosteroids
Number of subjects: 503
Study: 2137218

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg/day (group 1, n = 68)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Nifedipine 40 mg/day (group II, n = 68)
Number of subjects: 136
Study: 534846

Group type: EXPERIMENTAL
Intervention: Ligation of the testicular veins
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 96
Study: 30637626

Group type: EXPERIMENTAL
Intervention: GSK2798745 (TRPV4 channel blocker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSK2798745 (TRPV4 channel blocker) with high-fat meal
Number of subjects: 0
Study: 28471254

Group type: EXPERIMENTAL
Intervention: Guided self-help manual
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 24029724

Group type: COMPARATOR
Intervention: General trunk exercise programme (n=32)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Specific trunk exercise programme (n=29)
Number of subjects: 61
Study: 25457738

Group type: EXPERIMENTAL
Intervention: Self-referenced aIAT version
Number of subjects: 41

Group type: COMPARATOR
Intervention: 'Guilty/innocent' aIAT version
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: aIAT outcomes
Number of subjects: 41
Study: 22971278

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil combined with Anluohuaxian capsule for 48 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 72
Study: 19439433

Group type: EXPERIMENTAL
Intervention: Splint group (n = 33)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No-splint group (n = 36)
Number of subjects: 54
Study: 18004477

Group type: EXPERIMENTAL
Intervention: Palatal connective tissue graft
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) graft
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 22
Study: 11908355

Group type: EXPERIMENTAL
Intervention: New dentifrice containing 5.0% potassium nitrate and 0.454% stannous fluoride in a silica base (Colgate Sensitive Maximum Strength Toothpaste)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Commercially available desensitizing dentifrice containing 5.0% potassium nitrate and 0.243% sodium fluoride in a silica base (Sensodyne Fresh Mint Toothpaste)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Nondesensitizing dentifrice containing 0.243% sodium fluoride in a silica base (Colgate Winterfresh Gel)
Number of subjects: 109
Study: 8821519

Group type: EXPERIMENTAL
Intervention: Oral administration of diclofenac and codeine phosphate (50 mg each)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rectal administration of diclofenac and codeine phosphate (50 mg each)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Suppositories (rectal)
Number of subjects: 12
Study: 1573749

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 3936198

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil alone
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil and probenecid
Number of subjects: 184

Group type: COMPARATOR
Intervention: Amoxicillin plus probenecid
Number of subjects: 184
Study: 31010315

Group type: EXPERIMENTAL
Intervention: Recruitment via Facebook
Number of subjects: 138

Group type: COMPARATOR
Intervention: Recruitment via Twitter or Instagram
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Overall recruitment via social media
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Social media recruitment
Number of subjects: 138
Study: 28778455

Group type: EXPERIMENTAL
Intervention: rush oral immunotherapy (rOIT) for 3 months
Number of subjects: 45

Group type: COMPARATOR
Intervention: egg elimination diet (control)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: rush oral immunotherapy (rOIT) for 12 months
Number of subjects: 45
Study: 27238752

Group type: EXPERIMENTAL
Intervention: PegIFN (180μg/week) for 24 weeks followed by 24 weeks for early responders (arm A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PegIFN for another 24 weeks (arm B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PegIFN for another 72 weeks (arm C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PegIFN for another 72 weeks plus adefovir for 36 weeks (arm D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PegIFN for 48 weeks (control group)
Number of subjects: 0
Study: 25533009

Group type: EXPERIMENTAL
Intervention: Oral L-carnitine (20 mg/kg/day) for 12 months
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (no L-carnitine supplementation)
Number of subjects: 176
Study: 22757655

Group type: EXPERIMENTAL
Intervention: 1,800 mg G-GR
Number of subjects: 549

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 549
Study: 21076630

Group type: EXPERIMENTAL
Intervention: Aggressive lipid targets (LDL-C ≤ 70 mg/dL, non-HDL-C ≤ 100 mg/dL)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Standard lipid targets (LDL-C ≤ 100 mg/dL, non-HDL-C ≤ 130 mg/dL)
Number of subjects: 499
Study: 18760163

Group type: EXPERIMENTAL
Intervention: Adjustable fastening brace
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Compression garment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sports tape
Number of subjects: 15

Group type: COMPARATOR
Intervention: No support
Number of subjects: 15
Study: 15721120

Group type: EXPERIMENTAL
Intervention: Ethanol dose of 1 to 2 ml
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ethanol dose of >2 ml
Number of subjects: 42
Study: 12642173

Group type: EXPERIMENTAL
Intervention: Clomipramine (25 mg intravenously)
Number of subjects: 11

Group type: COMPARATOR
Intervention: No pharmacological challenge (control)
Number of subjects: 11
Study: 10333775

Group type: EXPERIMENTAL
Intervention: Dietitian-delivered nutrition counseling (2 individual and 2 group sessions over 6 weeks)
Number of subjects: 645
Study: 8942335

Group type: EXPERIMENTAL
Intervention: Rocuronium (group Roc)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Vecuronium (group Vec)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Atracurium (group Atr)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Pancuronium (group Pan)
Number of subjects: 56
Study: 1758526

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (PTx) in secondary hyperparathyroidism (group I)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (PTx) in primary hyperparathyroidism (group II)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Calcitriol (1 microgram/day) in chronic dialysis patients (group IV)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo in chronic dialysis patients (group IV)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (PTx) in cervicotomy patients (group III)
Number of subjects: 42
Study: 31670491

Group type: EXPERIMENTAL
Intervention: ProGlide
Number of subjects: 1987

Group type: COMPARATOR
Intervention: Prostar
Number of subjects: 1987
Study: 29506566

Group type: EXPERIMENTAL
Intervention: Laparoscopic inguinal ligament suspension (LILS)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Laparoscopic sacrocolpopexy (LSC)
Number of subjects: 107
Study: 26986459

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (paclitaxel 200 mg/m² and carboplatin AUC 5) followed by external radiotherapy (60 Gy/30 fractions/6 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (paclitaxel 200 mg/m² and carboplatin AUC 5) followed by accelerated hypofractionated radiotherapy (AHFx‐RT) (48 Gy/20 fractions/4 weeks) with concomitant chemotherapy (cisplatin 30 mg/m² weekly)
Number of subjects: 36
Study: 24438894

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 180
Study: 22510183

Group type: EXPERIMENTAL
Intervention: SABER‐Bupivacaine 5.0 mL (660 mg)
Number of subjects: 124

Group type: COMPARATOR
Intervention: SABER‐Placebo
Number of subjects: 124
Study: 20448126

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg (ATOR40)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg (ATOR10)
Number of subjects: 102
Study: 18500419

Group type: EXPERIMENTAL
Intervention: Sevoflurane via Anaesthetic Conserving Device (ACD)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 70
Study: 15593387

Group type: EXPERIMENTAL
Intervention: 99mTc‐TRODAT‐1 SPECT imaging
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (age-matched normal controls)
Number of subjects: 38
Study: 12805079

Group type: EXPERIMENTAL
Intervention: Intravenous low-dose ADMA
Number of subjects: 12
Study: 10536648

Group type: EXPERIMENTAL
Intervention: Chronic running + Hormone Replacement Therapy (HRT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Chronic running
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (Postmenopausal without HRT)
Number of subjects: 43
Study: 8777095

Group type: EXPERIMENTAL
Intervention: N2O-free anaesthetic
Number of subjects: 2478

Group type: COMPARATOR
Intervention: N2O regimen
Number of subjects: 2478
Study: 1836232

Group type: EXPERIMENTAL
Intervention: Tympanic thermometers
Number of subjects: 96

Group type: COMPARATOR
Intervention: Mercury-in-glass axillary thermometers
Number of subjects: 96

Group type: COMPARATOR
Intervention: Electronic axillary thermometers
Number of subjects: 96

Group type: COMPARATOR
Intervention: Mercury and electronic axillary methods
Number of subjects: 96
Study: 6120945

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta-blocker (metoprolol or oxprenolol)
Number of subjects: 0
Study: 29871544

Group type: EXPERIMENTAL
Intervention: Music & Memory (M&M) program
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 59
Study: 30694715

Group type: EXPERIMENTAL
Intervention: Genome-wide significant associations with DlCO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suggestive associations with DlCO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previously reported COPD loci associated with DlCO
Number of subjects: 0
Study: 28007924

Group type: EXPERIMENTAL
Intervention: Intravaginal metronidazole 750 mg plus miconazole 200 mg for 5 consecutive nights each month for 12 months
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo for 5 consecutive nights each month for 12 months
Number of subjects: 221
Study: 25965846

Group type: EXPERIMENTAL
Intervention: Iron treatment group (ITG) received 325 mg/day of ferrous sulphate daily.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Iron treatment group (ITG)
Number of subjects: 22
Study: 23812622

Group type: EXPERIMENTAL
Intervention: Passive leg raising (PLR) during tourniquet deflation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no PLR) during tourniquet deflation
Number of subjects: 70
Study: 21536810

Group type: EXPERIMENTAL
Intervention: Audiometer developed for hearing tests in a conference room
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clinical audiometer in a soundproof room
Number of subjects: 30
Study: 19678442

Group type: EXPERIMENTAL
Intervention: Adper Single Bond (SB)
Number of subjects: 84

Group type: COMPARATOR
Intervention: One Step (OS)
Number of subjects: 84
Study: 17972381

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AVE0118
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opioidergic system modulation
Number of subjects: 0
Study: 15741988

Group type: EXPERIMENTAL
Intervention: Two portions of fruits and vegetables (2 FV) daily for 14 days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Five portions of fruits and vegetables (5 FV) daily for 14 days
Number of subjects: 39
Study: 11971103

Group type: EXPERIMENTAL
Intervention: Active rTMS (n = 9)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham rTMS (n = 10)
Number of subjects: 19
Study: 9468162

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (4 microg/kg/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Norepinephrine alone
Number of subjects: 0
Study: 8562146

Group type: EXPERIMENTAL
Intervention: Tomudex 3.0 mg/m2 given once every 3 weeks
Number of subjects: 439

Group type: COMPARATOR
Intervention: 5‐fluorouracil (5‐FU) 425 mg/m2 and leucovorin (LV) 20 mg/m2 for 5 days (the Mayo regimen), given every 4‐5 weeks
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Tomudex
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 439
Study: 2698941

Group type: EXPERIMENTAL
Intervention: Cromakalim 1.5 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 1152354

Group type: EXPERIMENTAL
Intervention: Digitoxin tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Digitoxin elixir
Number of subjects: 0
Study: 31523848

Group type: EXPERIMENTAL
Intervention: Automated call
Number of subjects: 568

Group type: COMPARATOR
Intervention: Personal call
Number of subjects: 568
Study: 30284519

Group type: EXPERIMENTAL
Intervention: Nutrient cocktail composed of polyphenols, omega‐3 fatty acids, vitamin E, and selenium
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nutrient cocktail
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 20
Study: 28422709

Group type: EXPERIMENTAL
Intervention: Living within 600 meters of high voltage power lines
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control group (living farther than 600 meters from power lines)
Number of subjects: 285
Study: 25630040

Group type: EXPERIMENTAL
Intervention: KD-247 8mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KD-247 16mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KD-247 (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KD-247 (16mg/kg)
Number of subjects: 0
Study: 23510091

Group type: EXPERIMENTAL
Intervention: L‐NMMA (8 mg kg(‐1) h(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 21525253

Group type: EXPERIMENTAL
Intervention: High-MUFA ground beef (3.21 g more 18:1(n-9), 1.26 g less 18:0, 0.89 g less 16:0, and 0.36 g less 18:1(trans) fatty acids per patty)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Low-MUFA ground beef
Number of subjects: 27
Study: 19625785

Group type: EXPERIMENTAL
Intervention: rTMS (18,000 pulses over 3 weeks) + Citalopram (20 mg/day for 9 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham treatment + Citalopram (20 mg/day for 9 weeks)
Number of subjects: 62
Study: 16699970

Group type: EXPERIMENTAL
Intervention: 1 mg of glucagon
Number of subjects: 100

Group type: COMPARATOR
Intervention: 20 mg of scopolamine butylbromide
Number of subjects: 100
Study: 15056110

Group type: EXPERIMENTAL
Intervention: Light orthodontic forces (25 g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Heavy orthodontic forces (225 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (contralateral teeth)
Number of subjects: 10
Study: 11806864

Group type: EXPERIMENTAL
Intervention: High-dose glycine treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Atypical antipsychotics (clozapine or olanzapine)
Number of subjects: 33
Study: 9742977

Group type: EXPERIMENTAL
Intervention: Intensive blood-glucose control with metformin (n=342)
Number of subjects: 1704

Group type: COMPARATOR
Intervention: Addition of metformin in sulphonylurea-treated patients (n=268)
Number of subjects: 1704

Group type: EXPERIMENTAL
Intervention: Combined analysis of metformin-allocated patients
Number of subjects: 1704
Study: 7738908

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (3.6 mM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (without pentoxifylline)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pentoxifylline and Control
Number of subjects: 28
Study: 2929979

Group type: EXPERIMENTAL
Intervention: 10 mg sublingual nifedipine after weaning from bypass
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 mg sublingual nifedipine
Number of subjects: 20
Study: 4591000

Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride (Symmetrel)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29620722

Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib
Number of subjects: 2095

Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 2095
Study: 27965306

Group type: EXPERIMENTAL
Intervention: Intralesional (IL) injection
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intranodal (IN) injection
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both intralesional and intranodal (ILN) injection
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: DCIS patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: IBC patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: DCIS patients who achieved pCR
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: All patients who achieved pCR
Number of subjects: 54
Study: 25387312

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) with abacavir/lamivudine (ABC/3TC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) with tenofovir/emtricitabine (TDF/FTC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of ABC/3TC and TDF/FTC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of ABC/3TC and TDF/FTC at high viral loads
Number of subjects: 0
Study: 23276806

Group type: EXPERIMENTAL
Intervention: Rilpivirine 25 mg once daily
Number of subjects: 698

Group type: COMPARATOR
Intervention: Efavirenz 600 mg once daily
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Rilpivirine
Number of subjects: 698

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 698
Study: 21621992

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg b.i.d. for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 0
Study: 17368912

Group type: EXPERIMENTAL
Intervention: Visually masked associates presented at rapid rates during study phase.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonstudied test words presented for perceptual identification.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate tests after studying each list of associates.
Number of subjects: 0
Study: 16418872

Group type: EXPERIMENTAL
Intervention: Rowatinex 200 mg t.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen 600 mg t.i.d.
Number of subjects: 0
Study: 12945875

Group type: EXPERIMENTAL
Intervention: 40 mg enoxaparin once daily
Number of subjects: 0
Study: 10580782

Group type: EXPERIMENTAL
Intervention: Current users of lipid-lowering medications
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Past users of lipid-lowering medications
Number of subjects: 630

Group type: COMPARATOR
Intervention: Control group (non-users of lipid-lowering medications)
Number of subjects: 630
Study: 8656503

Group type: EXPERIMENTAL
Intervention: Lamivudine-zidovudine combination therapy (300 mg lamivudine every 12 hours + 200 mg zidovudine every 8 hours for 24 weeks)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Zidovudine monotherapy for 24 weeks
Number of subjects: 129
Study: 2252184

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg intramuscularly
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20